Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis

Xinan Wang; Donghui Tian; Jianfang Wang; Xiuhe Ouyang

doi:doi:10.11648/j.ajcem.20170501.15

| Peer-Reviewed

Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis

Xinan Wang, Donghui Tian, Jianfang Wang, Xiuhe Ouyang

Published in American Journal of Clinical and Experimental Medicine (Volume 5, Issue 1)

Received: 9 February 2017 Published: 10 February 2017

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Subheading: Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD. Objective: The research aims to quantitatively evaluate the serum MMP-9, inhibitors of TIMP-1, TNF-α, and OPG/RANK/RANKL in the patients with COPD accompanied by osteoporosis. Method: We selected 90 male patients with stable phase COPD who received treatment in our hospital from September 2012 to May 2014. They were divided into three groups by bone mineral density (BMD), COPD normal bone mass group, low bone mass group, and osteoporosis group of 30 patients each. MMP-9, TIMP-1, TNF-α, and OPG/RANK/RANKL were detected with the ELISA method. The ELISA method was used to detect the levels of serum bone alkaline phosphatase (sBAP), serum osteocalcin (sOC), serum type I collagen cross-linked C telopeptide (sCTX). Result: There were significant differences in BMI and CAT scores between the osteoporosis group, the normal bone mass group, and the low bone mass group (P<0.01). The bone density of lumbar vertebra in the low bone mass group and the osteoporosis group decreased when compared with that in the normal bone mass group. The differences were statistically significant (P<0.05, P<0.01). The density of femoral neck in the low bone mass group and the osteoporosis group was significantly lower than that in the normal bone mass group. And there were significant differences (P<0.01). There were significant differences in level of serum MMP-9 among the three groups (P<0.01). Conclusion: MMP-9, TNF-α, and OPG/RANK/RANKL may play a collaborative role in occurrence and progression of pulmonary parenchyma damage and osteoporosis.

Published in	American Journal of Clinical and Experimental Medicine (Volume 5, Issue 1)
DOI	10.11648/j.ajcem.20170501.15
Page(s)	19-25
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2017. Published by Science Publishing Group

Keywords

Chronic Obstructive Pulmonary Disease, Bone Mineral Density, Osteoporosis, Matrix Metalloproteinase

References

[1]	Yang L, He Q. [Effects of inhaled corticosteroids on osteoporosis in patients with chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 2015; 38: 777-779.
[2]	Brinchault G, Diot P, Dixmier A, Goupil F, Guillais P, Gut-Gobert C, Leroyer C, Marchand-Adam S, Meurice JC, Morel H, Person C, Cavailles A. [Comorbidities of COPD]. Rev Pneumol Clin 2015; 71: 342-349.
[3]	Terasaki J, Singh G, Zhang W, Wagner P, Sharma G. Using EMR to improve compliance with clinical practice guidelines for management of stable COPD. Respir Med 2015; 109: 1423-1429.
[4]	Takahashi S, Betsuyaku T. The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries. Respir Investig 2015; 53: 259-270.
[5]	Kooman JP, Shiels PG, Stenvinkel P. Premature aging in chronic kidney disease and chronic obstructive pulmonary disease: similarities and differences. Curr Opin Clin Nutr Metab Care 2015; 18: 528-534.
[6]	Ajmera M, Sambamoorthi U, Metzger A, Dwibedi N, Rust G, Tworek C. Multimorbidity and COPD Medication Receipt Among Medicaid Beneficiaries With Newly Diagnosed COPD. Respir Care 2015; 60: 1592-1602.
[7]	Liu WT, Kuo HP, Liao TH, Chiang LL, Chen LF, Hsu MF, Chuang HC, Lee KY, Huang CD, Ho SC. Low bone mineral density in COPD patients with osteoporosis is related to low daily physical activity and high COPD assessment test scores. Int J Chron Obstruct Pulmon Dis 2015; 10: 1737-1744.
[8]	Durup D, Jorgensen HL, Christensen J, Tjonneland A, Olsen A, Halkjaer J, Lind B, Heegaard AM, Schwarz P. A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D and Cardiovascular Disease Mortality: The CopD Study. J Clin Endocrinol Metab 2015; 100: 2339-2346.
[9]	Jorgensen TS, Hansen AH, Sahlberg M, Gislason GH, Torp-Pedersen C, Andersson C, Holm E. Nationwide time trends and risk factors for in-hospital falls-related major injuries. Int J Clin Pract 2015; 69: 703-709.
[10]	Corsonello A, Scarlata S, Pedone C, Bustacchini S, Fusco S, Zito A, Incalzi RA. Treating COPD in Older and Oldest Old Patients. Curr Pharm Des 2015; 21: 1672-1689.
[11]	Chen SJ, Liao WC, Huang KH, Lin CL, Tsai WC, Kung PT, Chang KH, Kao CH. Chronic obstructive pulmonary disease and allied conditions is a strong independent risk factor for osteoporosis and pathologic fractures: a population-based cohort study. QJM 2015; 108: 633-640.
[12]	Pandrea I, Landay A, Wilson C, Stock J, Tracy R, Apetrei C. Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities. Curr HIV/AIDS Rep 2015; 12: 54-67.
[13]	Chubachi S, Nakamura H, Sasaki M, Haraguchi M, Miyazaki M, Takahashi S, Tanaka K, Funatsu Y, Asano K, Betsuyaku T. Polymorphism of LRP5 gene and emphysema severity are associated with osteoporosis in Japanese patients with or at risk for COPD. Respirology 2015; 20: 286-295.
[14]	Bousquet J, Anto JM, Berkouk K, Gergen P, Antunes JP, Auge P, Camuzat T, Bringer J, Mercier J, Best N, Bourret R, Akdis M, Arshad SH, Bedbrook A, Berr C, Bush A, Cavalli G, Charles MA, Clavel-Chapelon F, Gillman M, Gold DR, Goldberg M, Holloway JW, Iozzo P, Jacquemin S, Jeandel C, Kauffmann F, Keil T, Koppelman GH, Krauss-Etschmann S, Kuh D, Lehmann S, Carlsen KC, Maier D, Mechali M, Melen E, Moatti JP, Momas I, Nerin P, Postma DS, Ritchie K, Robine JM, Samolinski B, Siroux V, Slagboom PE, Smit HA, Sunyer J, Valenta R, Van de Perre P, Verdier JM, Vrijheid M, Wickman M, Yiallouros P, Zins M. Developmental determinants in non-communicable chronic diseases and ageing. Thorax 2015; 70: 595-597.
[15]	Matera MG, Cardaci V, Cazzola M, Rogliani P. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf 2015; 14: 533-541.
[16]	McGarvey L, Lee AJ, Roberts J, Gruffydd-Jones K, McKnight E, Haughney J. Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population. Respir Med 2015; 109: 228-237.
[17]	Chun P. Role of sirtuins in chronic obstructive pulmonary disease. Arch Pharm Res 2015; 38: 1-10.
[18]	Malinovschi A, Masoero M, Bellocchia M, Ciuffreda A, Solidoro P, Mattei A, Mercante L, Heffler E, Rolla G, Bucca C. Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients. Respir Res 2014; 15: 131.
[19]	Watanabe R, Tanaka T, Aita K, Hagiya M, Homma T, Yokosuka K, Yamakawa H, Yarita T, Tai N, Hirano J, Inoue D, Okazaki R. Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab 2015; 33: 392-400.
[20]	Park SJ, Foreman MG, Demeo DL, Bhatt SP, Hansel NN, Wise RA, Soler X, Bowler RP. Menthol cigarette smoking in the COPDGene cohort: relationship with COPD, comorbidities and CT metrics. Respirology 2015; 20: 108-114.
[21]	Malik RD, Lapin B, Wang CE, Lakeman JC, Helfand BT. Are we testing appropriately for low testosterone?: Characterization of tested men and compliance with current guidelines. J Sex Med 2015; 12: 66-75.
[22]	Lin YH, Tsai CL, Chien LN, Chiou HY, Jeng C. Newly diagnosed gastroesophageal reflux disease increased the risk of acute exacerbation of chronic obstructive pulmonary disease during the first year following diagnosis--a nationwide population-based cohort study. Int J Clin Pract 2015; 69: 350-357.
[23]	A VR. Inhalational Steroids and Iatrogenic Cushing's Syndrome. Open Respir Med J 2014; 8: 74-84.
[24]	Khow KS, Yong TY. Atypical femoral fracture in a patient treated with denosumab. J Bone Miner Metab 2015; 33: 355-358.
[25]	Chee C, Sellahewa L, Pappachan JM. Inhaled corticosteroids and bone health. Open Respir Med J 2014; 8: 85-92.
[26]	Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Chron Obstruct Pulmon Dis 2014; 9: 1145-1154.
[27]	Escamilla R. [COPD: beyond the respiratory system]. Presse Med 2014; 43: 1381-1386.

Cite This Article

Plain Text BibTeX RIS

APA Style

Xinan Wang, Donghui Tian, Jianfang Wang, Xiuhe Ouyang. (2017). Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis. American Journal of Clinical and Experimental Medicine, 5(1), 19-25. https://doi.org/10.11648/j.ajcem.20170501.15

Copy | Download

ACS Style

Xinan Wang; Donghui Tian; Jianfang Wang; Xiuhe Ouyang. Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis. Am. J. Clin. Exp. Med. 2017, 5(1), 19-25. doi: 10.11648/j.ajcem.20170501.15

Copy | Download

AMA Style

Xinan Wang, Donghui Tian, Jianfang Wang, Xiuhe Ouyang. Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis. Am J Clin Exp Med. 2017;5(1):19-25. doi: 10.11648/j.ajcem.20170501.15

Copy | Download

@article{10.11648/j.ajcem.20170501.15,
  author = {Xinan Wang and Donghui Tian and Jianfang Wang and Xiuhe Ouyang},
  title = {Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {5},
  number = {1},
  pages = {19-25},
  doi = {10.11648/j.ajcem.20170501.15},
  url = {https://doi.org/10.11648/j.ajcem.20170501.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20170501.15},
  abstract = {Subheading: Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD. Objective: The research aims to quantitatively evaluate the serum MMP-9, inhibitors of TIMP-1, TNF-α, and OPG/RANK/RANKL in the patients with COPD accompanied by osteoporosis. Method: We selected 90 male patients with stable phase COPD who received treatment in our hospital from September 2012 to May 2014. They were divided into three groups by bone mineral density (BMD), COPD normal bone mass group, low bone mass group, and osteoporosis group of 30 patients each. MMP-9, TIMP-1, TNF-α, and OPG/RANK/RANKL were detected with the ELISA method. The ELISA method was used to detect the levels of serum bone alkaline phosphatase (sBAP), serum osteocalcin (sOC), serum type I collagen cross-linked C telopeptide (sCTX). Result: There were significant differences in BMI and CAT scores between the osteoporosis group, the normal bone mass group, and the low bone mass group (PConclusion: MMP-9, TNF-α, and OPG/RANK/RANKL may play a collaborative role in occurrence and progression of pulmonary parenchyma damage and osteoporosis.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis
AU  - Xinan Wang
AU  - Donghui Tian
AU  - Jianfang Wang
AU  - Xiuhe Ouyang
Y1  - 2017/02/10
PY  - 2017
N1  - https://doi.org/10.11648/j.ajcem.20170501.15
DO  - 10.11648/j.ajcem.20170501.15
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 19
EP  - 25
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20170501.15
AB  - Subheading: Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD. Objective: The research aims to quantitatively evaluate the serum MMP-9, inhibitors of TIMP-1, TNF-α, and OPG/RANK/RANKL in the patients with COPD accompanied by osteoporosis. Method: We selected 90 male patients with stable phase COPD who received treatment in our hospital from September 2012 to May 2014. They were divided into three groups by bone mineral density (BMD), COPD normal bone mass group, low bone mass group, and osteoporosis group of 30 patients each. MMP-9, TIMP-1, TNF-α, and OPG/RANK/RANKL were detected with the ELISA method. The ELISA method was used to detect the levels of serum bone alkaline phosphatase (sBAP), serum osteocalcin (sOC), serum type I collagen cross-linked C telopeptide (sCTX). Result: There were significant differences in BMI and CAT scores between the osteoporosis group, the normal bone mass group, and the low bone mass group (PConclusion: MMP-9, TNF-α, and OPG/RANK/RANKL may play a collaborative role in occurrence and progression of pulmonary parenchyma damage and osteoporosis.
VL  - 5
IS  - 1
ER  -

Copy | Download

Author Information

Xinan Wang

Department of Internal Respiratory, Binzhou People's Hospital, Binzhou, P. R. China
Donghui Tian

Department of Internal Neurology, Binzhou People's Hospital, Binzhou, P. R. China
Jianfang Wang

Department of Public Health, Binzhou People's Hospital, Binzhou, P. R. China
Xiuhe Ouyang

Department of Internal Respiratory, Binzhou People's Hospital, Binzhou, P. R. China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Xinan Wang, Donghui Tian, Jianfang Wang, Xiuhe Ouyang. (2017). Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis. American Journal of Clinical and Experimental Medicine, 5(1), 19-25. https://doi.org/10.11648/j.ajcem.20170501.15

Copy | Download

ACS Style

Xinan Wang; Donghui Tian; Jianfang Wang; Xiuhe Ouyang. Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis. Am. J. Clin. Exp. Med. 2017, 5(1), 19-25. doi: 10.11648/j.ajcem.20170501.15

Copy | Download

AMA Style

Xinan Wang, Donghui Tian, Jianfang Wang, Xiuhe Ouyang. Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis. Am J Clin Exp Med. 2017;5(1):19-25. doi: 10.11648/j.ajcem.20170501.15

Copy | Download

@article{10.11648/j.ajcem.20170501.15,
  author = {Xinan Wang and Donghui Tian and Jianfang Wang and Xiuhe Ouyang},
  title = {Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {5},
  number = {1},
  pages = {19-25},
  doi = {10.11648/j.ajcem.20170501.15},
  url = {https://doi.org/10.11648/j.ajcem.20170501.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20170501.15},
  abstract = {Subheading: Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD. Objective: The research aims to quantitatively evaluate the serum MMP-9, inhibitors of TIMP-1, TNF-α, and OPG/RANK/RANKL in the patients with COPD accompanied by osteoporosis. Method: We selected 90 male patients with stable phase COPD who received treatment in our hospital from September 2012 to May 2014. They were divided into three groups by bone mineral density (BMD), COPD normal bone mass group, low bone mass group, and osteoporosis group of 30 patients each. MMP-9, TIMP-1, TNF-α, and OPG/RANK/RANKL were detected with the ELISA method. The ELISA method was used to detect the levels of serum bone alkaline phosphatase (sBAP), serum osteocalcin (sOC), serum type I collagen cross-linked C telopeptide (sCTX). Result: There were significant differences in BMI and CAT scores between the osteoporosis group, the normal bone mass group, and the low bone mass group (PConclusion: MMP-9, TNF-α, and OPG/RANK/RANKL may play a collaborative role in occurrence and progression of pulmonary parenchyma damage and osteoporosis.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Research on the Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD Accompanied by Osteoporosis
AU  - Xinan Wang
AU  - Donghui Tian
AU  - Jianfang Wang
AU  - Xiuhe Ouyang
Y1  - 2017/02/10
PY  - 2017
N1  - https://doi.org/10.11648/j.ajcem.20170501.15
DO  - 10.11648/j.ajcem.20170501.15
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 19
EP  - 25
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20170501.15
AB  - Subheading: Role of Matrix Metalloproteinase in the Patients with Stable Phase COPD. Objective: The research aims to quantitatively evaluate the serum MMP-9, inhibitors of TIMP-1, TNF-α, and OPG/RANK/RANKL in the patients with COPD accompanied by osteoporosis. Method: We selected 90 male patients with stable phase COPD who received treatment in our hospital from September 2012 to May 2014. They were divided into three groups by bone mineral density (BMD), COPD normal bone mass group, low bone mass group, and osteoporosis group of 30 patients each. MMP-9, TIMP-1, TNF-α, and OPG/RANK/RANKL were detected with the ELISA method. The ELISA method was used to detect the levels of serum bone alkaline phosphatase (sBAP), serum osteocalcin (sOC), serum type I collagen cross-linked C telopeptide (sCTX). Result: There were significant differences in BMI and CAT scores between the osteoporosis group, the normal bone mass group, and the low bone mass group (PConclusion: MMP-9, TNF-α, and OPG/RANK/RANKL may play a collaborative role in occurrence and progression of pulmonary parenchyma damage and osteoporosis.
VL  - 5
IS  - 1
ER  -

Copy | Download